The undifferentiated pleomorphic sarcoma market is anticipated to grow at a CAGR of 4.50% during the forecast period of 2024-2032, fueled by an increasing emphasis on tailored treatments and advancements in immune-oncology approaches across the 8 major markets.
Base Year
Historical Year
Forecast Year
Undifferentiated pleomorphic sarcoma (UPS) is a high-grade and rare soft-tissue sarcoma. The market is witnessing growth with rising awareness for personalized medicine, and the application of immunotherapies. Regulatory approvals and funding for early diagnosis further contribute to market growth, thus, facilitating innovation in oncology care to address the complex needs of undifferentiated pleomorphic sarcoma patients.
Rising Prevalence of Undifferentiated Pleomorphic Sarcoma Drives Market Growth
The increasing incidence of undifferentiated pleomorphic sarcoma (UPS), also known as malignant fibrous histiocytoma (MFH) is a primary factor propelling the market growth. According to the American Cancer Society, around 13,590 new cases of soft-tissue sarcoma were expected to be diagnosed in the United States in 2024, leading to approximately 5,200 deaths. The increasing awareness around the disease is creating demand for novel treatment options, thereby enhancing market growth.
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
Market Segmentation Based on the Treatment Type Set to Witness Substantial Growth
Based on treatment type, the market is segmented into radiation therapy (external beam radiation, intraoperative radiation therapy, and others), chemotherapy, targeted drug therapy, and immunotherapy. Among these, immunotherapy is expected to dominate the market, driven by the adoption of immune checkpoint inhibitors like pembrolizumab (Keytruda) and nivolumab (Opdivo). These drugs function by inhibiting the PD-1 pathway, which cancer cells frequently exploit to avoid detection by the immune system. The growing advancements in molecular biology and the increasing demand for personalized medicine are anticipated to bolster market growth during the forecast period.
Based on region, the market report offers insights into the United States, Germany, France, Italy, Spain, the United Kingdom, Japan, and India. Among these, the United States is expected to lead the market due to the presence of key pharmaceutical companies and significant healthcare spending. Strong research initiatives and governmental support for cancer research are contributing to the growth of the local market.
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Bayer AG is a leading pharmaceutical company, headquartered in Germany. The company develops numerous drugs, including Vitrakvi (larotrectinib). It is a TRK inhibitor for treating tumors including undifferentiated pleomorphic sarcoma with NTRK gene fusions.
Nanobiotix S.A. is a biotechnology company that develops nanomedicines for cancer treatment. The company was e...
The company was founded in 1849. They have developed Sutent (sunitinib), a multi-kinase inhibitor used to trea...
Novartis AG is a global pharmaceutical company based in Basel, Switzerland. The focus of this company has been...
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other companies include Epizyme, Inc., Gradalis, Inc., Advenchen Laboratories LLC, Philogen S.p.A, Chugai Pharmaceutical Co., Ltd., CytRx Corp., GlaxoSmithKline Plc., Agilent Technologies, Taiho Pharmaceutical Co., Ltd, KaryoPharm Therapeutics Inc., and Lytix Biopharma AS.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share